inVentiv Health Launches Two Global SAGs


Organization Launches Two Global Site Advisory Groups at Society for Clinical Research Sites' Global Site Solutions Summit

  BOCA RATON, FL - inVentiv Health, a global professional services organization designed to help the biopharmaceutical industry accelerate the delivery of much-needed therapies to market, today announced the launch of two global Site Advisory Groups (SAGs) at the annual Global Site Solutions Summit. These activities are part of the company's commitment to enhanced collaboration with investigative sites, who are essential partners in trial success.   "Clinical trial sites are on the forefront of successful trials. Recognizing this, we're bringing clinical trial stakeholders together to create more innovative approaches to trial development. By working directly with sites, we can better address the challenges they face and leverage their rich insights," said Susan Stansfield, Ph.D., Executive Vice President, Site Centricity Unit, Clinical Division. "This increased collaboration will allow us to enhance site resource offerings."   The goal of the inVentiv-hosted SAGs is to serve as forums to pinpoint key areas for improvement in the critical study start-up phase where incremental changes can have a significant impact on overall trial results. These SAGs, which will include global representation, include: 

  • Site Coordinator SAG: inVentiv believes that understanding the perspective of site coordinators, who are on the front lines of research and manage a myriad of functions, will lead to measurable improvements in trial speed and improved site satisfaction. This SAG will provide an open forum for coordinators to discuss pain points they experience that are ripe for innovative approaches and solutions.

  • Oncology SAG: Driven by unmet patient needs, oncology continues to remain a key therapeutic focus area for biopharmaceutical companies. This SAG will bring together Primary Investigators (PIs) with significant oncology experience to address the unique challenges related to this important therapeutic category. inVentiv will collaborate with the PIs to develop enhanced protocol designs with the ultimate goal of getting critically needed products to patients.

Leaders from inVentiv Health's Site Centricity Unit (SCU) will explore ways to further collaborate with sites by leading and participating in key discussions at the Summit on Saturday, October 15:  

Susan Stansfield, Executive Vice President, Site Centricity Unit

SITEVISION 2020™ – Panelist (8:50-9:45 am) Uncover Realities to Become the "Site of Choice" – Breakout Moderator (1:00-2:00 pm)  

Nancy Perrella, Senior Director, QA & RC

Surviving a Regulatory Inspection – Breakout Panelist (2:30-3:00 pm)   The SCU, comprised of site effectiveness and efficiency experts, was created to provide focused attention and constant innovation at the site level. The group works to understand site needs and develops resources to support sites in delivering enhanced trial execution. For example, SCU has created a Site Relationship Manager who can be deployed to the most heavily utilized sites to streamline operations and uncover actionable insights.   View a

video about SCU and inVentiv Health

to learn more.  

About inVentiv Health

inVentiv Health is a global professional services organization designed to help the biopharmaceutical industry accelerate the delivery of much-needed therapies to market. Our combined Clinical Research Organization (CRO) and Contract Commercial Organization (CCO) offer a differentiated suite of services, processes and integrated solutions that improve client performance. With more than 15,000 employees and the ability to support clients in 90 countries, our global scale and deep therapeutic expertise enable inVentiv to help clients successfully navigate an increasingly complex environment. For more information, visit


Related Videos
Greg Ball, Founder, ASAP Process Consulting image credit screen shot from video
Janice Chang, CEO, TransCelerate BioPharma @ video screenshot.
Applied Clinical Trials and LabConnect
Cat Hall endpoint Clinical
OM1 Sonja Wustrack
Related Content
© 2024 MJH Life Sciences

All rights reserved.